Articles from Polyphron

Polyphron, a company building artificial human biology to transform drug development and treat disease, announced $20M in seed financing led by Quiet Capital, with participation from Gradient, Haystack, and Compound. Polyphron trains frontier AI models to manufacture and simulate living tissue to create the verification substrate for AI-driven biology.